Table 1.
Clinical course and longitudinal outcomes in LGI1 antibody encephalitis patients.
| Case, age/gender | Presenting features | Treatment | Flortaucipir PET | Final outcome | ||||
|---|---|---|---|---|---|---|---|---|
| Months from onset | Cognitive function | Global SUVR 1 | AD Summary SUVR 2 | Months from onset | Cognitive function | |||
| A, 35 y/M | Small fiber and autonomic neuropathy, followed by subacute‐onset memory loss, inattention and mental status change. | Steroids, IVIg, rituximab | 4.2 | CDR 0.5; CDRsb 2.0 | 1.12 | 1.05 | 36.0 | Cognitively normal; CDR 0; CDRsb 0 |
| B, 63 y/M | Subacute‐onset psychosis and FBDS. | Steroids, IVIg | 36.4 | CDR 0.5; CDRsb 3.0 | 1.21 | 1.32 | 48.0 | Very mild impairmentCDR 0.5; CDRsb 4.0 |
| C, 67 y/M | Subacute‐onset psychosis with FBDS. | Steroids, IVIg, rituximab | 18.4 | CDR 0; CDRsb 0 | 1.12 | 1.16 | 48.0 | Cognitively normal; CDR 0; CDRsb 0 |
| D, 83y/F | Subacute‐onset memory loss and psychoses with FBDS associated with altered consciousness. | Steroids, IVIg, rituximab | 54.6 | CDR 2; CDRsb 14.0 | 1.48 | 1.97 | 57.0 | Deceased |
AD, Alzheimer disease; CDR, Clinical Dementia Rating®; CDRsb, CDR sum‐of‐boxes; FBDS, faciobrachial dystonic seizures; IVIg, intravenous immunoglobulin (0.4 g/kg × 5 days); rituximab, 375 mg/m2 Q7 days × 4; steroids, methylprednisolone 1 g × 5 days, followed by prolonged oral taper); SUVR, standardized uptake value ratios.
Global SUVR reflects the average SUVR across all cortical regions. For comparison, mean Global SUVR was 1.11 ± 0.1 in cognitive normal individuals and 1.43 ± 0.25 in individuals with early‐symptomatic AD.
AD Summary SUVR reflects the average SUVR within regions commonly affected in AD, including the left and right inferior temporal cortex, amygdala, entorhinal cortex, and lateral occipital cortices. 25 For comparison, mean AD Summary SUVR was 1.16 ± 0.21 in cognitive normal individuals and 1.99 ± 0.64 in individuals with early‐symptomatic AD.